| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2013-11-26 | Algeta (Norway) | Bayer (Germany) | €2.1 billion | Oncology |
| 2013-11-19 | EOS (Ethical Oncology Science) (Italy) | Clovis Oncology (USA) | up to $420 million (€310 million) | Cancer - Oncology |
| 2013-11-19 | Patheon (USA) | Royal DSM (The Netherlands) JLL Partners (USA) | $2.6 billion | production |
| 2013-11-12 | Scil Proteins Production (Germany) | Wacker Chemie (Germany) | undisclosed | production |
| 2013-11-11 | Novartis diagnostics business unit (Switzerland) | Grifols (Spain) | $ 1.675 billion (€1.24 billion) | diagnostic |
| 2013-11-11 | Viropharma (USA) | Shire (UK - USA) | $4.2 billion (€3.13 billion) | Rare diseases |
| 2013-10-31 | CRM Clinical Trials GmbH (Germany) | Venn Life Sciences (Ireland) | €0.6 million | CRO |
| 2013-10-15 | Spirogen (UK) | MedImmune (USA - global biologics arm of AstraZeneca (UK) | up to $240 million (€177.2 million) | Cancer - Oncology |
| 2013-10-11 | genomic activities of Imaxio (France) | Hybrigenics (France) | undisclosed | services |
| 2013-10-07 | TAP Biosystems (UK) | Sartorius Stedim Biotech (Germany - France) | €33 million | |
| 2013-10-03 | Arixtra and Fraxiparine/Fraxodi brands and GSK manufacturing site | Aspen Global Incorporated (South Africa) | £700 million (€838,7 million) | |
| 2013-10-01 | Onyx Pharmaceuticals (USA - CA) | Amgen (USA - CA) | $9.7 Billion | Cancer- Oncology |
| 2013-09-23 | Ixico (UK) | Phytopharm (UK) | £5.6 million (€6.65 million) | medical imaging analysis |
| 2013-09-16 | Cornerstone Therapeutics (USA) | Chiesi (Italy) | specialty pharmaceuticals |
|
| 2013-09-12 | Molecular Profiles (UK) | Columbia Laboratories (USA) | $25 million (€15.8 million) | drug development |
| 2013-09-06 | Wilex Inc (USA), wholly owned US subsidiary of Wilex (Germany) | Nuclea Biotechnologies (USA) | in vitro diagnostic |
|
| 2013-09-03 | BioFire Diagnostics (USA) | bioMérieux (France) | $450 million acquisition price and the company’s net financial debt | Molecular biology |
| 2013-08-30 | Acton Pharmaceuticals (USA) | Meda (Sweden) | $ 135 million (€102 million) and milestones | Allergic diseases |
| 2013-08-28 | Peptisyntha (Belgium) | International Chemical Investors Group (ICIG) (Germany) | peptides |
|
| 2013-08-26 | Amplimmune (USA) | MedImmune (USA - global biologics arm of AstraZeneca (UK) | up to $275 million | Cancer-Oncology |
